Sawai Acquires Sumitomo Stake In Generic Joint Venture
This article was originally published in PharmAsia News
Executive SummarySawai Pharmaceutical acquired Sumitomo Shoji's 30 percent stake in Medisa Shinyaku June 18, making the generic drug maker a Sawai wholly owned subsidiary
You may also be interested in...
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.